Services

Histology

Pharmacology

Medical Device Testing

In Vitro Screening

Animal Model Development

Custom Assay Development

Vivarium Rental

Toxicology

Species

Non-human Primates

Dogs

Mini-pigs / Pigs

Rabbits

Mice

Rats

Sheep

Guinea Pigs

Hamsters

Other Species

Therapeutic Areas

Oncology

Immunology & Inflammation

Neurology / CNS

Cardiovascular

Dermatology & Wound Healing

Metabolism

Gastroenterology

Hepatology

Pulmonology

Infectious Diseases & Sepsis

Musculoskeletal

Nephrology & Urology

Capabilities

GLP / IND-Enabling Studies

Small and Large Animal Housing

Bioanalytical Platforms

About

News

Contact

Career

Request a Quote

Logo
☰
  • Services ⌄
    • Histology
    • Pharmacology
    • Medical Device Testing
    • In Vitro Screening
    • Animal Model Development
    • Custom Assay Development
    • Vivarium Rental
    • Toxicology
  • Species ⌄
    • Non-human Primates
    • Dogs
    • Mini-pigs / Pigs
    • Rabbits
    • Mice
    • Rats
    • Sheep
    • Guinea Pigs
    • Hamsters
    • Other Species
  • Therapeutic Areas ⌄
    • Oncology
    • Immunology & Inflammation
    • Neurology / CNS
    • Cardiovascular
    • Dermatology & Wound Healing
    • Metabolism
    • Gastroenterology
    • Hepatology
    • Pulmonology
    • Infectious Diseases & Sepsis
    • Musculoskeletal
    • Nephrology & Urology
  • Capabilities ⌄
    • GLP / IND-Enabling Studies
    • Small and Large Animal Housing
    • Bioanalytical Platforms
  • About ⌄
    • News
  • Contact ⌄
    • Career
    • Request a Quote

How This CRISPR Biotech Could Make Investors Rich

  • Post author:Sam
  • Post published:December 26, 2017
  • Post category:BioPharma

A look at a biotech company that represents a solid trend in the industry. Source: BioSpace

Continue ReadingHow This CRISPR Biotech Could Make Investors Rich

Array Biopharma Spun Off Heart Drug R&D Into New Subsidiary Yarra Therapeutics

  • Post author:Sam
  • Post published:December 26, 2017
  • Post category:BioPharma

It appears that what Array is trying to do is focus on oncology while the new subsidiary focuses on rare diseases. Source: BioSpace

Continue ReadingArray Biopharma Spun Off Heart Drug R&D Into New Subsidiary Yarra Therapeutics

The Number 1 Small-Cap Biotech Investors are Missing Out On

  • Post author:Sam
  • Post published:December 26, 2017
  • Post category:BioPharma

A look at a small-cap biotech company that investors should consider. Source: BioSpace

Continue ReadingThe Number 1 Small-Cap Biotech Investors are Missing Out On

Mallinckrodt Takes Out Sucampo in Surprising $1.2B Deal

  • Post author:Sam
  • Post published:December 26, 2017
  • Post category:BioPharma

Mallinckrodt picks up Sucampo’s Amitiza as well as two other pipeline compounds. Source: BioSpace

Continue ReadingMallinckrodt Takes Out Sucampo in Surprising $1.2B Deal

Maryland's Precision Medicine Group Lands $275M

  • Post author:Sam
  • Post published:December 26, 2017
  • Post category:BioPharma

The round was led by Berkshire Partners and TPG Growth, with participation from its co-founders and management team, as well as original investors Oak Investment Partners and J.H. Whitney. Source:…

Continue ReadingMaryland's Precision Medicine Group Lands $275M

SoCal's Peregrine Names a New CEO, to Change Name to Avid Bioservices

  • Post author:Sam
  • Post published:December 26, 2017
  • Post category:BioPharma

Dr. Lias succeeds Steven W. King, who resigned as president and chief executive officer of Peregrine to pursue other professional interests. Source: BioSpace

Continue ReadingSoCal's Peregrine Names a New CEO, to Change Name to Avid Bioservices

Shire Plans to Hire in 2018 for its Georgia Manufacturing Site

  • Post author:Sam
  • Post published:December 26, 2017
  • Post category:BioPharma

Shire filed its first submission to the FDA for its new plasma manufacturing site in Covington, Georgia. Source: BioSpace

Continue ReadingShire Plans to Hire in 2018 for its Georgia Manufacturing Site

Novartis' Tasigna Wins FDA Nod for First and Only CML Therapy With Treatment-Free Remission Data …

  • Post author:Sam
  • Post published:December 26, 2017
  • Post category:BioPharma

Novartis announced today that the FDA approved the inclusion of Treatment-free Remission data in the Tasigna U.S. product label. Source: BioSpace

Continue ReadingNovartis' Tasigna Wins FDA Nod for First and Only CML Therapy With Treatment-Free Remission Data …

Novartis Can be Sued for Damage Caused by Generics California Court Rules

  • Post author:Sam
  • Post published:December 26, 2017
  • Post category:Drug Industry Daily

In a result that could have far-reaching implications for brand-name drug manufacturers, the California Supreme Court unanimously ruled Novartis can be held liable for injuries caused by generics of its…

Continue ReadingNovartis Can be Sued for Damage Caused by Generics California Court Rules

United Therapeutics Settles Federal Kickback Lawsuit for $210 Million

  • Post author:Sam
  • Post published:December 26, 2017
  • Post category:Drug Industry Daily

United Therapeutics agreed to pay $210 million to resolve Justice Department claims that the drugmaker collaborated with charity Caring Voice Coalition (CVC) to boost sales of United’s pulmonary arterial hypertension…

Continue ReadingUnited Therapeutics Settles Federal Kickback Lawsuit for $210 Million
  • Go to the previous page
  • 1
  • …
  • 216
  • 217
  • 218
  • 219
  • 220
  • 221
  • 222
  • …
  • 610
  • Go to the next page

Stay Connected

Keep up with the latest news & insights.

Contact Us

Phone:
+1 858-605-5882
Fax:
+1 858-605-5916
Email:
info@biolegacyresearch.com
Mail:

6042 Cornerstone Court W

Suite E

San Diego, CA 92121

Social:
© 2025 BioLegacy Research. All rights reserved.